The website outlines a blend of clinical residency and research at Carnegie Mellon. Projects like the calf thorax model for robotic IMA harvest and the printing of fibre architecture show a strong focus on mechanical properties in tissue engineering. The mention of a custom bioreactor and specific stiffness variations adds technical depth. It is clear that there is an emphasis on creating functional tissue rather than just structural scaffolds. The contact information and scholar profiles are easy to find, making it straightforward to follow the academic trajectory. The funding details provide some context on the scale of the research efforts being undertaken by the team.
Questions about Syed Faaz Ashraf
What is Syed Faaz Ashraf?
Syed Faaz Ashraf is a clinical PGY-6 integrated cardiothoracic surgery resident at the University of Pittsburgh with a research focus on congenital cardiac surgery and cardiovascular tissue engineering. He has three years of NIH-funded research experience at Carnegie Mellon University where he developed conduits, instruments, and software related to congenital heart disease.
What specific medical problem does this research address?
The business focuses on developing bioengineered pulsatile Fontan conduits designed to act as a sub-pulmonary neo-ventricle for patients with single-ventricle disease. These conduits aim to restore the sub-pulmonary pump and generate 5–10 mmHg of subpulmonic pressure.
What materials and methods are used in the conduit development?
The research utilizes mouse-scale collagen conduits that are FRESH 3D-bioprinted at three different stiffnesses and cellularised with human stem-cell-derived cardiomyocytes and cardiac fibroblasts. These conduits were matured in a custom bioreactor before being implanted in SCID/beige mice.
What results have been observed in the animal studies?
The developed conduits stayed patent and contractile up to a year in vivo, generating 8–10 mmHg of pulsatile pressure at six months. The collagen remodelled into vascularised neo-tissue, and the conduits captured on field stimulation at 1 and 2 Hz.
Who are the collaborators and what is the funding source?
The research team includes Feinberg Lab at Carnegie Mellon University, with funding from NIH/NHLBI grant F32HL165847. The principal investigator held this grant from 2022 to 2024 with a total value of $145,616.
What awards and recognitions has the work received?
The project has received recognition including a President's Award Paper from the Congenital Heart Surgeons' Society in 2025 and was a finalist for the Lillehei Award at AATS 2025. It was also presented at AHA Scientific Sessions 2024.
What other technologies and models are part of the research scope?
The research involves additional ventures with Cures Collaborative and focuses on areas such as 3D bioprinting, tissue engineering, mechatronics, and computer vision. Specific projects include a calf thorax model for robotic internal mammary artery harvest.
What software tools have been created for this research?
The team developed CardioConduitNet, a deep-learning pipeline that segments a contractile engineered conduit on ultrasound. It separates respiratory from cardiac motion and reports regional contractility, which clinical echo software cannot currently do.
What is the ultimate goal of the Fontan conduit project?
The research aims to create a contractile conduit with valves to restore the sub-pulmonary pump in patients who carry the long-term morbidity of a Fontan circulation. The goal is to print, seed, and implant a pulsatile conduit of engineered heart tissue.
What specific limitation of current medical devices does this research solve?
The research addresses the problem that ePTFE conduits used in Fontan circulation neither contract nor grow with the child, leaving pulmonary flow passive. The aim is to create a pulsatile conduit that actively generates pressure.
What surgical models have been developed to aid in research?
The work includes contributions to a calf thorax model for robotic internal mammary artery harvest, which is part of the broader cardiovascular tissue engineering efforts. This model helps in understanding surgical procedures for congenital heart disease.
Where has the research been published and presented?
The research has been presented at major conferences including AHA Scientific Sessions 2024, where it was published in Circulation. The specific publication reference is Circulation. 2024;150(Suppl 1):A4144448.
What specialized equipment is used in the laboratory?
The team has developed a custom bioreactor for maturing the conduits and uses dual-plane ultrasound for imaging the contractile engineered conduit. These tools are essential for monitoring the development and function of the tissue-engineered hearts.
What cell types are used in the tissue engineering process?
The research involves the use of human stem-cell-derived cardiomyocytes and cardiac fibroblasts to cellularise the conduits. This approach allows for the creation of functional tissue that can contract and generate pressure.
What is the official website of Syed Faaz Ashraf?
The official website of Syed Faaz Ashraf is faazashraf.com.
AI-generated from reviews on this page. Verify anything important with the company directly.
Syed Faaz Ashraf presents a sophisticated portfolio of projects bridging clinical cardiothoracic surgery with advanced tissue engineering and mechatronics. The primary focus on creating a contractile Fontan conduit that generates pulsatile pressure addresses a critical limitation in single-ventricle disease treatment. The use of FRESH 3D-bioprinting to replicate the native ventricle’s fibre architecture is a notable technical achievement, aiming to restore the sub-pulmonary pump rather than relying on passive flow. The accompanying CardioConduitNet deep-learning pipeline further enhances this work by automating the segmentation of ultrasound data, distinguishing respiratory from cardiac motion to report regional contractility with high precision. With NIH funding and recognition from the Congenital Heart Surgeons’ Society, the integration of computer vision with bioprinting demonstrates a rigorous, multidisciplinary approach to solving complex congenital heart defects. The detailed evidence of conduit patency and tissue remodeling in vivo supports the potential for these engineered solutions to eventually replace current standard grafts, offering a more physiological restoration of hemodynamics for pediatric patients.
While the descriptions of the bioprinted conduits and deep-learning software are compelling, the manuscripts are still in writing for submission to Science Translational Medicine. It is important to verify the final publication status before assuming these techniques are fully validated or widely adopted in clinical practice. The funding details are clear, but the transition from mouse models to human application remains a step away.
The CardioConduitNet pipeline looks very useful for analyzing ultrasound data efficiently.
The work on the Fontan conduit that pumps is truly remarkable. Generating pulsatile pressure in vivo with engineered heart tissue represents a significant leap for congenital cardiac surgery. Seeing the collagen conduits remain contractile and vascularized for up to a year in mouse models demonstrates exceptional durability and biological integration. This level of innovation in tissue engineering is exactly what the field needs to advance patient outcomes beyond passive grafts.
News
No news yet. This is where the business shares its own updates and press.
Photos
Widgets
Get the widget for your site →About Syed Faaz Ashraf
Syed Faaz Ashraf is a clinical PGY-6 integrated cardiothoracic surgery resident at the University of Pittsburgh, with a research focus on congenital cardiac surgery and cardiovascular tissue engineering. His work includes three years of NIH-funded research at Carnegie Mellon, where he has developed conduits, instruments, and software related to congenital heart disease. Specific projects involve a bioengineered pulsatile Fontan conduit designed to act as a sub-pulmonary neo-ventricle, as well as related work in 3D bioprinting, tissue engineering, mechatronics, and computer vision. He has also contributed to a calf thorax model for robotic internal mammary artery harvest and is associated with projects such as the Replistruder 4.5 bioprinter and CardioConduitNet software.
- Website
- faazashraf.com
- ashrafsf@upmc.edu
- Categories
- Hospital & health care, Medical devices, Biotechnology